← Back to Browse

Kamada Ltd.

KMDA • Healthcare

⇄ Compare
71
Grade B
Compass

About Kamada Ltd.

Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division.

Current Price
$7.12
Market Cap
$408M

Quality Assessment

Kamada Ltd. is a above-average quality healthcare company with a Compass Score of 71. Solid fundamentals, with a few weaker spots. Worth a look for a diversified portfolio.

Score Breakdown

The Compass Score is based on 6 quality factors identified by academic research.

Click any factor to see detailed metrics

Valuation Metrics

Click any metric for details

Fair Value

Pro

See whether this stock trades above or below its fair value.

Wall Street View

Consensus
Buy
Analysts
2
Price Target
🔒
Upside
🔒

Catalyst Signal

Plus

Recent earnings beats and analyst-upgrade momentum. How it works

Catalyst Score
🔒
EPS Beat Streak
🔒
Net Upgrades (180d)
🔒

See recent earnings beats and analyst-upgrade momentum.

Analyst Track Record

Plus

See each covering analyst's historical hit rate.

Financial Health

Plus

Click any metric for details

See bankruptcy-risk and financial-strength scores for this company.

Growth Projections

Plus
Projected EPS Growth
🔒
Projected Revenue Growth
🔒

See projected EPS and revenue growth for this company.

Technical Overview

Click any metric for details

Similar High-Quality Stocks

REGN

Regeneron Pharmaceuticals, Inc.

86
$664.52
Grade A

ADUS

Addus HomeCare Corporation

86
$108.21
Grade A

ALGN

Align Technology, Inc.

86
$179.45
Grade A

AMGN

Amgen Inc.

86
$363.39
Grade A

ARQT

Arcutis Biotherapeutics, Inc.

86
$27.74
Grade A

AMN

AMN Healthcare Services, Inc.

85
$32.37
Grade A

Important Disclaimer

The Compass Score is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always do your own research and consider consulting a financial advisor before making investment decisions.